Bérangère Bastien

Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial

Élisabeth Quoix, Rodryg Ramlau, Virginie Westeel et al. · The Lancet Oncology · 2011 · 265 citations

Medicine, Immunology, Oncology +15

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial

Élisabeth Quoix, H. Léna, György Losonczy et al. · The Lancet Oncology · 2015 · 207 citations

Medicine, Immunology, Oncology +13

Safety and immunogenicity of the therapeutic vaccine TG1050 in chronic hepatitis B patients: a phase 1b placebo-controlled trial

Fabien Zoulim, Claire Fournier, François Habersetzer et al. · Human Vaccines & Immunotherapeutics · 2019 · 87 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17

The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up

Diane M. Harper, Pekka Nieminen, Gilbert Donders et al. · Gynecologic Oncology · 2019 · 72 citations · Full text

Veterinary Medicine, Immunology, Oncology +17

Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC

Caroline Tosch, Bérangère Bastien, Luc Barraud et al. · Journal for ImmunoTherapy of Cancer · 2017 · 66 citations · Full text

Life Sciences, Immunology, Oncology +17